Altrenogest structure
|
Common Name | Altrenogest | ||
|---|---|---|---|---|
| CAS Number | 850-52-2 | Molecular Weight | 310.430 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 495.6±45.0 °C at 760 mmHg | |
| Molecular Formula | C21H26O2 | Melting Point | 120ºC | |
| MSDS | N/A | Flash Point | 210.1±21.3 °C | |
Use of AltrenogestAltrenogest(A35957; RU2267) is a progestogen structurally related to veterinary steroid trenbolone.Target: Progesterone ReceptorAltrenogest is a progestogen structurally related to veterinary steroid trenbolone. Treatment of embryo-recipient mares with altrenogest appears to be beneficial in extending the degree of donor-recipient synchrony required for successful embryo transfer. Altrenogest treatment also seems to be conductive to pregnancy maintenance in recipients experiencing luteal dysfunction [1]. The oil and gel altrenogest preparations are equally effective in modulating estrous behavior and time to estrus and ovulation. Altrenogest treatment started late in diestrus appears to result in a high incidence of ovulation during treatment and when luteolysis and ovulation occur during treatment; the subsequent luteal phase is frequently prolonged due to failure of regression of the CL [2]. |
| Name | Altrenogest |
|---|---|
| Synonym | More Synonyms |
| Description | Altrenogest(A35957; RU2267) is a progestogen structurally related to veterinary steroid trenbolone.Target: Progesterone ReceptorAltrenogest is a progestogen structurally related to veterinary steroid trenbolone. Treatment of embryo-recipient mares with altrenogest appears to be beneficial in extending the degree of donor-recipient synchrony required for successful embryo transfer. Altrenogest treatment also seems to be conductive to pregnancy maintenance in recipients experiencing luteal dysfunction [1]. The oil and gel altrenogest preparations are equally effective in modulating estrous behavior and time to estrus and ovulation. Altrenogest treatment started late in diestrus appears to result in a high incidence of ovulation during treatment and when luteolysis and ovulation occur during treatment; the subsequent luteal phase is frequently prolonged due to failure of regression of the CL [2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 495.6±45.0 °C at 760 mmHg |
| Melting Point | 120ºC |
| Molecular Formula | C21H26O2 |
| Molecular Weight | 310.430 |
| Flash Point | 210.1±21.3 °C |
| Exact Mass | 310.193268 |
| PSA | 37.30000 |
| LogP | 3.49 |
| Vapour Pressure | 0.0±2.9 mmHg at 25°C |
| Index of Refraction | 1.594 |
| InChIKey | VWAUPFMBXBWEQY-ANULTFPQSA-N |
| SMILES | C=CCC1(O)CCC2C3CCC4=CC(=O)CCC4=C3C=CC21C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| WGK Germany | 3.0 |
|---|---|
| RTECS | KG7745000 |
| HS Code | 2937290090 |
| HS Code | 2937290090 |
|---|
| (17b)-17-Hydroxy-17-(2-propenyl)estra-4,9,11-trien-3-one |
| 13b-Methyl-17a-allyl-D4,9,11-gonatriene-17b-ol-3-one |
| (17β)-17-Hydroxy-17-(2-propenyl)estra-4,9,11-trien-3-one |
| Estra-4,9,11-trien-3-one, 17-hydroxy-17-(2-propen-1-yl)-, (17β)- |
| Allyltrenbolone |
| r2267 |
| 17α-Allyl-17-hydroxyestra-4,9,11-trien-3-one |
| altregonest |
| (17β)-17-hydroxy-17-(prop-2-en-1-yl)estra-4,9,11-trien-3-one |
| Altrenogest |
| REGU-MATE |
| 17-allyltrenbolone |
| ru2267 |
| Estra-4,9,11-trien-3-one, 17-α-allyl-17-hydroxy- |
| (8S,13S,14S,17R)-17-Allyl-17-hydroxy-13-methyl-1,2,6,7,8,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one |
| drc6246 |
| Estra-4,9,11-trien-3-one, 17β-hydroxy-17-(2-propenyl)- |
| Regumate |
| 17a-Allyl-17-hydroxyestra-4,9,11-trien-3-one |